

Complex Product Characterization – Most useful Techniques

Rationale for sampling, and batch-to-batch variability for various types of complex products

Dr A Malleswara Reddy

Head | Analytical Research and Development
Dr Reddy's Laboratories Limited, India

FY 2021 Generic Drug Science and Research Initiatives Public Workshop – June 23, 2021

| Name of the test | Most useful Technique |
|---|---------------------------------|
| Liposome Size Distribution | Zeta Sizer |
| Morphology- lamellarity, Bilayer thickness | Cryo-TEM |
| Lipid bilayer transition | Nano-DSC |
| Physical state of active substance inside the liposomes | SAXS |
| Free and encapsulated drug | Size exclusion followed by HPLC |
| In-Vitro Drug Release | SEC, Ultra centrifugation |
| Internal pH | Ultra filtration |
| Drug Related Impurities | LC, LCMS |
| Lipid Related impurities | LC-RI, ELSD, CAD |

Characterisation of long acting Injectable (Polymer Based)

| Name of the test for Polymer Characterization | Most useful Technique | Product Characterization | Most Useful technique |
|---|----------------------------|--------------------------|---|
| Polymer composition(L:G) | ¹ H-NMR | Size Distribution | LD / SEM |
| Polymer molecular weight | GPC-MALLS/GPC-RI | Drug Distribution | Raman |
| Degree of Branching | GPC-MALLS/RI/ Viscosity | Porosity | Hg porosity meter |
| Block Length | ¹³ C NMR | Trace components | NMR/LC-MS |
| Residual monomers | GC/NMR | Drug Release | USP IV, Bottle rotating Test Tube/Water bath |
| Metal catalysts | ICP-OES/MS | | |
| End Group chemistry | NMR / Potentiometry | | |
| Glass transition temperature | DSC | | |

| Name of the test | Most useful Technique | Most Useful technique |
|------------------------------------|-----------------------------------|-----------------------|
| Primary structure | N-Terminal sequencer | LC-HRMS |
| Secondary structure | Circular Dichroism | FT-IR / Raman |
| Tertiary /higher order structures | SEC-UV SEC/A4F-MALLS | SV-AUC NMR |
| Impurities characterisation | HPLC/UPLC HILIC / Ion-Exchange | LC-HRMS |
| Isoelectric point | Capillary Electrophoresis | |
| Bio-Assay | Cell based Assays | |

| Name of the test | Most useful Technique | Most Useful technique |
|--------------------------------|-----------------------------|------------------------|
| Particle Size Distribution | Zeta Sizer | Cryo-TEM |
| Molecular weight Distribution | GPC | MALLS |
| Low molecular weight Complexes | Dialysis / Ultra filtration | ICP-MS |
| Labile Iron | Iron Chelation Assay | Bleomycin Assay |
| Surface Charge | Zeta Potential | |
| Iron Core Size and Morphology | AFM | TEM |
| Crystallinity | XRD, Synchrotron | Raman, TEM-SEAD, XANES |
| Iron Environment | Mossbauer spectroscopy | ESR/EPR, Raman, UV-Vis |
| Redox Potential | Polarography | Cerimetric titration |
| Magnetic Properties | VSM | SQUID |
| Carbohydrate Shell | FT-IR / NMR | SEC |

| Name of the test | Most useful Technique | Most Useful technique |
|--------------------------|------------------------|---------------------------|
| Size Distribution | Laser Diffraction | Flow -CAM |
| Morphology | SEM | Morphology G3 |
| Crystallinity | XRD | Raman |
| Rheology | Rheometer | Viscometer |
| Surface tension | Tensiometer | |
| Drop Size and Drop assay | LC-Assay - HPLC | |
| IVRT | Flow Through Apparatus | Bottle rotating Apparatus |
| Polymer Equivalence | SEC -MALLS | |

Rationale for sampling, and batch-to-batch variability for various types of complex products

- Method variability (standard deviation)
- Product (batch to batch) variability
- No. of lots needed to represent reference product variability
- Establishment of equivalence criteria
- Setting specification

Note : Acceptance criteria depends on totality of the analytical data and not simply on the observed range of product attributes of the reference product. This is because some product attributes act in combination to affect a product's safety, purity, and potency profile; therefore, their potential interaction should be considered when conducting the comparative analytical assessment and setting specifications.

- Min-Max range along with analytical method variability
- X-Sigma: 3σ (**coverage 99.7%**)
- Tolerance Interval (coverage : 95 to 99% and confidence 95%)


Inferential statistical methods: Allowing for a statistical quantification.

- Equivalence test (for Means)
- Multivariate analysis


Note : Inferential statistics can quantify uncertainty

– e.g. false positive rate alpha restricted to 5%, power for a given sample size & deviation from H0

Statistical approaches for comparative assessment using X-Sigma




Molecular weight distribution by size exclusion chromatography of 687 Copaxone® batches manufactured between 2005 and 2008.



The data on Peak average molecular weight, Higher molecular weight at - 1SD, Lower molecular weight at +1SD of 687 batches of Copaxone® that are presented by Innovator in the Citizen petition to USFDA dated 13th Nov-2009

- If the test results are variable, then tolerance interval of the data can be used.
- A **tolerance interval** is a statistical **interval** within which, with some confidence level, a specified proportion of a sampled population falls. (Eg ; 95%, 99% CI)
- Rationale for Sample size (n): Risk based Approach
Eg : 95% CI , 99% population
- Decision based on Coverage of Population and method uncertainty.



Example: Average molecular weight comparison of test and reference product

p value is found to be more than 0.05,

The difference between the means is not statistically significant

Two-Sample T-Test and CI: Reference, Test

Method

μ_1 : mean of Reference

μ_2 : mean of Test

Difference: $\mu_1 - \mu_2$

Equal variances are assumed for this analysis.

Descriptive Statistics

| Sample | N | Mean | StDev | SE Mean |
|-----------|----|------|-------|---------|
| Reference | 10 | 6938 | 698 | 221 |
| Test | 7 | 6673 | 352 | 133 |

Estimation for Difference


| Difference | Pooled StDev | 95% CI for Difference |
|------------|--------------|-----------------------|
| 265 | 585 | (-349, 880) |

Test

Null hypothesis $H_0: \mu_1 - \mu_2 = 0$

Alternative hypothesis $H_1: \mu_1 - \mu_2 \neq 0$

| T-Value | DF | P-Value |
|---------|----|---------|
| 0.92 | 15 | 0.372 |



Quantification of spectral difference for insulin human drug substances (DSs) from HumulinR® (black) and NovolinR® (red) in pH 7 buffer. The superimposed 1D ^1H NMR spectra of the 2 representative lots of DSs are shown (a). Blinded spectral regions shown in gray were excluded in principal component analysis (PCA).

The PCA scores are plotted

between PC1 and PC2 (b) and between PC1 and PC3 (c). The 90% confidence ellipses are drawn for each brand of insulin human

Similarity scores for the observable HOS relevant signals were expressed in the unitless **Mahalanobis distance (D_M)** derived from PCA space with an unsupervised **chemometric approach**

THANKS

Dr A Malleswara Reddy

Head | Analytical Research and Development
Dr Reddy's Laboratories Limited, India

malleswarareddy@drreddys.com